A recent study has shown encouraging evidence for the long-term efficacy of fenfluramine in the treatment of Dravet syndrome, a rare and therapy-resistant epilepsy syndrome.The research, carried out by the University of Antwerp, built on an earlier study of add-on fenfluramine treatment in 12 patients with Dravet syndrome, which was published in 2012. The findings suggested that the drug has a beneficial long-term response, but further research was needed.During the current study, the researchers monitored 10 subjects from the initial investigation (average age 24 years) for five years, between 2010 and 2014. They found that at least three of the 10 subjects were seizure-free for the entire five years, whilst a further four experienced periods of seizure freedom that lasted at least two years. Fenfluramine was shown to be well-tolerated, with no signs of pulmonary hypertension, another reassuring finding.The research concludes: “These findings support the long-term control of convulsive seizures by low-dose fenfluramine, while being well tolerated in this cohort of patients with Dravet syndrome.”This study is published in the medical journal Epilepsia.Click here for more articles about other treatments for epilepsy.